| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6660300 | EMD SERONO INC | Method of use of a biphasic controlled release delivery system for high solubility pharmaceuticals and method |
Mar, 2018
(6 years ago) | |
| US6475521 | EMD SERONO INC | Biphasic controlled release delivery system for high solubility pharmaceuticals and method |
Mar, 2018
(6 years ago) | |
Glucophage Xr is owned by Emd Serono Inc.
Glucophage Xr contains Metformin Hydrochloride.
Glucophage Xr has a total of 2 drug patents out of which 2 drug patents have expired.
Expired drug patents of Glucophage Xr are:
- US6660300
- US6475521
Glucophage Xr was authorised for market use on 13 October, 2000.
Glucophage Xr is available in tablet, extended release;oral dosage forms.
Glucophage Xr can be used as method of treating patient with type 2 diabetes by once daily administration.
The generics of Glucophage Xr are possible to be released after 19 March, 2018.
Drugs and Companies using METFORMIN HYDROCHLORIDE ingredient
Market Authorisation Date: 13 October, 2000
Treatment: Method of treating patient with type 2 diabetes by once daily administration
Dosage: TABLET, EXTENDED RELEASE;ORAL
GLUCOPHAGE XR family patents
